Navigation Links
UT Southwestern receives continued NIH funding for Inner City Asthma Consortium
Date:11/22/2009

DALLAS Nov. 23, 2009 UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

The ICAC, which receives funding through the NIH's National Institute of Allergy and Infectious Diseases, investigates novel treatments and causes of asthma in urban children.

Dr. Rebecca Gruchalla, chief of allergy and immunology at UT Southwestern, said continued funding of the consortium is imperative because morbidity and mortality continues to be highest in inner-city children and adolescents with asthma. Dr. Gruchalla has led the Dallas arm of the ICAC for seven years.

"The proposed studies undertaken through our continued role in the ICAC are novel, innovative and likely to help us truly make a difference in the lives of inner-city children suffering from this often debilitating disease," Dr. Gruchalla said.

Ongoing studies include a prospective, longitudinal evaluation of environmental factors that influence the development of the immune system and asthma, as well as clinical trials of possible treatment therapies.

Previous ICAC-funded research has found that:

  • A coordinated, guidelines-based approach to asthma management quickly controls asthma among inner-city adolescents.
  • Adding exhaled nitric oxide to guidelines-based care does not improve clinical outcomes.
  • Screening tests used to predict asthma activity in some patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens.

With continued NIH funding, Dr. Michelle Gill, assistant professor of pediatrics at UT Southwestern, is leading key mechanistic studies that explore how anti-IgE therapy can decrease viral-induced seasonal asthma exacerbations. IgE antibodies are the fuel in the immune system that perpetuates asthmatic reactions and can make asthma worse in people who are sensitive to particular allergens.

"The goal of our mechanistic studies is to define how allergens interfere with immune responses to respiratory viruses. We will also investigate whether anti-IgE therapy improves these responses to seasonal viral infections in patients with asthma," Dr. Gill said.

The consortium is administered by the University of Wisconsin-Madison. In addition to UT Southwestern, research is being conducted at Boston University School of Medicine; Children's Memorial Hospital in Chicago; George Washington University School of Medicine and Health Sciences in Washington, D.C.; National Jewish Health in Denver; Johns Hopkins University School of Medicine; University of California, San Francisco; Columbia University College of Physicians and Surgeons in New York City; and the Henry Ford Hospital in Detroit.


'/>"/>

Contact: Erin Prather Stafford
erin.pratherstafford@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Director of UT Southwestern center honored with first international neurology medal
2. UT Southwestern Responds to VA Announcement
3. UT Southwestern physicians bust myths about insulin
4. UT Southwestern researchers launch study into search-and-destroy antigen for deadly skin cancer
5. Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find
6. Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report
7. UT Southwestern, UT Arlington to develop magnetic surgery tools
8. UT Southwestern researcher named HHMI Early Career Physician-Scientist
9. Former Gov. Bill Clements Makes Historic Gift to UT Southwestern With $100 Million Transformative Contribution
10. UT Southwesterns Olson wins prestigious French award for heart research
11. Participants in antidepressant drug trials are atypical patients, UT Southwestern researchers report
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT Southwestern receives continued NIH funding for Inner City Asthma Consortium
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
Breaking Medicine Technology: